Metis TechBio-P (07666.HK): AiTEM AI Formulation Platform Partners with HENGRUI PHARMA to Accelerate Drug Formulation Development

NewTimeSpace News: Metis TechBio Co., Ltd. (07666.HK) issued a voluntary announcement on August 3, 2026, disclosing that its self-developed AiTEM AI formulation innovation platform will be deployed locally at Jiangsu HENGRUI PHARMA to accelerate drug formulation development efficiency. This collaboration marks the continued realization of the external commercial closed loop for the NanoForge-powered AiTEM platform.

AiTEM is powered by the Company's proprietary AI nano-delivery platform NanoForge as its technology engine, utilizing proprietary algorithms for drug formulation design and optimization. NanoForge is the world's first AI-driven nano-delivery platform, having accumulated over 10 million lipid structures and 100,000 experimental data points, empowering the Company to advance more than 10 first-in-class or best-in-class pipelines and achieving breakthroughs in targeted delivery to 8 key organs and tissues. In the MTS004 project, China's first AI-powered novel formulation drug to complete Phase III clinical trials, AiTEM shortened the preclinical formulation optimization cycle from the industry average of 1–2 years to just 3 months.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.